Jordan Sloshower, MD, MSc
Clinical Instructor of Psychiatry
Research & Publications
Biography
News
Research Summary
Jordan's research focuses on therapeutic applications of psychedelic substances and in particular, how psychedelics can be combined optimally with psychotherapy and other healing modalities to treat mental health conditions, including depression and PTSD. Jordan is currently an investigator and therapist in two clinical trials of psilocybin-assisted therapy in the treatment of major depressive disorder. This research investigates potential neurobiological and psychological mechanisms of action, namely induction of neuroplasticity and psychological flexibility. He is also a clinical investigator in MAPS’ Expanded Access Program for MDMA-assisted therapy of PTSD.
Coauthors
Selected Publications
- Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and TraineesPrueitt WL, Sloshower J. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Academic Psychiatry 2022, 47: 74-77. PMID: 35616783, PMCID: PMC9134971, DOI: 10.1007/s40596-022-01662-9.
- Research abuses against people of colour and other vulnerable groups in early psychedelic researchStrauss D, de la Salle S, Sloshower J, Williams MT. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal Of Medical Ethics 2021, 48: 728-737. PMID: 34253622, DOI: 10.1136/medethics-2021-107262.
- Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frameSloshower J, Guss J, Krause R, Wallace R, Williams M, Reed S, Skinta M. Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal Of Contextual Behavioral Science 2020, 15: 12-19. DOI: 10.1016/j.jcbs.2019.11.002.
- Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model ClinicSloshower J. Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. 2018, 113-132. DOI: 10.1007/978-3-319-76720-8_7.
- Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic PsychedelicsSchindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.
- Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trialSloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.
- Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptomsSkosnik P, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal Of Psychopharmacology 2023, 37: 687-697. PMID: 37392016, DOI: 10.1177/02698811231179800.
- The DEA report on ayahuasca risks: “Science” in service of prohibition?Labate B, Ermakova A, Sloshower J, Galvão-Coelho N, Palhano-Fontes F, Antunes H, Loures de Assis G, Cavnar C, de Araújo D, Ribeiro S. The DEA report on ayahuasca risks: “Science” in service of prohibition? Journal Of Psychedelic Studies 2023, 7: 81-89. DOI: 10.1556/2054.2023.00279.
- Single-Dose Psilocybin Treatment for Major Depressive DisorderRaison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.
- The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)Guss, J., Krause, R. & Sloshower, J. (2020, August 13). The Yale Manual for Psilocybin- Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). https://doi.org/10.31234/osf.io/u6v9y
- Online Sales of Unscheduled Pharmaceutical AgentsGupta S, Wallace R, Sloshower J. Online Sales of Unscheduled Pharmaceutical Agents. Journal Of Addiction Medicine 2017, 11: 411-412. PMID: 28742625, DOI: 10.1097/adm.0000000000000342.
- Pathways of HIV Risk and Vulnerability Among New Female Sex Workers in Northern Karnataka, IndiaSloshower, J. (2014). “Pathways of HIV Risk and Vulnerability Among New Female Sex Workers in Northern Karnataka, India.” EliScholar – Yale Medicine Thesis Digital Library.
- Capturing Suffering: Ethical Considerations of Bearing Witness and the Use of PhotographySloshower J. Capturing Suffering: Ethical Considerations of Bearing Witness and the Use of Photography. The International Journal Of The Image 2013, 3: 11-22. DOI: 10.18848/2154-8560/cgp/v03i02/44079.
- Descent into quiet chaos: the story of Mr. F.Sloshower J. Descent into quiet chaos: the story of Mr. F. Connecticut Medicine 2012, 76: 423-4. PMID: 23248868.
- Describing the content of primary care: limitations of Canadian billing dataKatz A, Halas G, Dillon M, Sloshower J. Describing the content of primary care: limitations of Canadian billing data. BMC Primary Care 2012, 13: 7. PMID: 22335900, PMCID: PMC3305652, DOI: 10.1186/1471-2296-13-7.
- Negotiating Pharmaceutical Politics and Ethics: Democracy, Citizenship and Medical Activism in ThailandSloshower, J. (2010). Negotiating Pharmaceutical Politics and Ethics: Democracy, Citizenship and Medical Activism in Thailand. Lambert Academic Publishing